The epidermal growth factor receptor (EGFR) is a transmembrane protein classified as a tyrosine kinase. EGFR is often shown to be overexpressed in certain human carcinoma cells which leads to enhanced activation of the anti-apoptotic Ras signal transduction cascades, subsequently resulting in increased survival of cancer cells and uncontrolled cell proliferation. EGFR inhibitors bind to the ATP-binding site and inhibit tyrosine kinase, the downstream signaling cascades are also inhibited, resulting in inhibited malignant cell proliferation. EGFR inhibitors are indicated for the treatment of non-small cell lung cancer, breast cancer, thyroid cancer, pancreatic cancer, and solid tumors. Amgen, AstraZeneca, Boehringer Ingelheim, Jiangsu Hengrui Pharma, Sanofi, Daiichi Sankyo Company, and Eli Lilly & Company are some of the major players in the EGFR inhibitors market.
Key Market Developments:
- In Jan 2022, Betta Pharmaceuticals registered Icotinib for non-small cell lung cancer in China.
- In Jun 2022, Takeda Oncology launched Brigatinib for non-small cell lung cancer in Poland.
- In Dec 2022, Jiangsu Hansoh Pharmaceutical preregistered Aumolertinib for non-small cell lung cancer in the European Union.
Approved Drug Molecules and Brand Names for EGFR Inhibitors:
- Erbitux (Cetuximab)
- Erlotinib
- Gefitinib
- Lapatinib
- Vectibix (Panitumumab)
- Tagrisso (Osimertinib)
- Gilotrif (Afatinib)
- Irene (Pyrotinib)
- Caprelsa (Vandetanib)
- TheraCIM (Nimotuzumab)
- Conmana (Icotinib)
- Nerlynx (Neratinib)
- Vizimpro (dacomitinib)
- Ameile (Aumolertinib)
- Alunbrig (Brigatinib)
- Leclaza (Lazertinib)
- Ivesa (Furmonertinib)
- Portrazza (Necitumumab)
- Rybrevant (Amivantamab-vmjw)
Drugs under the Pipeline for EGFR Inhibitors:
- Ganetespib (ADX-1612)
- Varlitinib (ASLAN001)
- Tesevatinib (KD019)
- Sapitinib (AZD8931)
- Exkivity (Mobocertinib)
- Fujovee (Abivertinib)
- Futuximab/Modotuximab (S95026)
- Pimurutamab (HLX07)
- HuMax-EGFR (Zalutumumab)
- Xegafri (Rociletinib)
- Hocena (Antroquinonol)
- Nazartinib (EGF816)
- Ruserontinib (SKLB-1028)
- Sunvozertinib (DZD9008)
- BMS690514
- Olita (Olmutinib)
- Izalontamab (SI-B001)
- Rintega (Rindopepimut)
- Tarlox (Tarloxotinib bromide)
- Naquotinib (ASP8273)
- Oritinib (SH-1028)
- CimaVax EGF (EGF-PTI)
- SYN004
- Depatuxizumab (ABT-806)
- Imgatuzumab (RO5083945)
- Matuzumab (EMD 72000)
- AC480
- CDX-3379
- CUDC-101
- Semena (Befotertinib)
- TY-9591 and others
Clinical Activity and Developments of EGFR Inhibitors:
Currently, there are more than 140 drug products in the EGFR inhibitors, including 19 approved drug products and the rest of them are in the clinical development phases.
- In May 2023, AstraZeneca completed a phase-I pharmacokinetics trial for non-small cell lung cancer in the USA, Belgium, South Korea, Netherlands, Taiwan and UK for Osimertinib.
- In Jun 2023, Dizal Pharmaceuticals released pooled efficacy data from a phase-I/II WUKONG1 trial in non-small cell lung cancer for Sunvozertinib.
|
Molecule Name |
Number of Studies |
|
Ganetespib (ADX-1612) |
36 |
|
Varlitinib (ASLAN001) |
20 |
|
Tesevatinib (KD019) |
15 |
|
Sapitinib (AZD8931) |
14 |
|
Exkivity (Mobocertinib) |
13 |
|
Fujovee (Abivertinib) |
13 |
|
Futuximab/Modotuximab (S95026) |
13 |
|
Pimurutamab (HLX07) |
13 |
|
HuMax-EGFR (Zalutumumab) |
11 |
|
Xegafri (Rociletinib) |
11 |
|
Hocena (Antroquinonol) |
10 |
|
Nazartinib (EGF816) |
10 |
|
Ruserontinib (SKLB-1028) |
9 |
|
Sunvozertinib (DZD9008) |
9 |
|
BMS690514 |
8 |
|
Olita (Olmutinib) |
8 |
|
Izalontamab (SI-B001) |
8 |
|
Rintega (Rindopepimut) |
7 |
|
Tarlox (Tarloxotinib bromide) |
7 |
|
Naquotinib (ASP8273) |
7 |
|
Oritinib (SH-1028) |
7 |
|
CimaVax EGF (EGF-PTI) |
6 |
|
SYN004 |
6 |
|
Depatuxizumab (ABT-806) |
6 |
|
Imgatuzumab (RO5083945) |
6 |
|
Matuzumab (EMD 72000) |
6 |
|
AC480 |
5 |
|
CDX-3379 |
5 |
|
CUDC-101 |
5 |
|
Semena (Befotertinib) |
5 |
|
TY-9591 |
5 |
Target Indication Analysis of EGFR Inhibitors
EGFR inhibitors such as afatinib, almonertinib, brigatinib, dacomitinib, erlotinib, gefitinib, and others are approved for the treatment of non-small cell lung cancer. Lapatinib, neratinib, and pyrotinib are approved for the treatment of breast cancer. Vandetanib is indicated for the treatment of thyroid cancer, erlotinib for pancreatic cancer, and simotinib for solid tumors. The drugs that are in clinical trials for conditions such as colorectal cancer, gastric cancer, squamous cell cancer, acute myeloid leukemia, liver cancer, esophageal cancer, liver cancer, ovarian cancer, and others.
Regional Analysis of EGFR Inhibitors
EGFR Inhibitors Market
Eli Lilly & Company’s Erbitux had a total sale of US$ 566 million in 2022, including US$ 500 million sales in the USA alone. According to the World Health Organization’s cancer report 2020, there were 1,92,92,789 new cases of cancer globally, in 2020. Breast cancer was the most common cancer occurring in women (22,61,419 patients globally), with the highest number of cancer rates in the USA (253,465 patients), followed by France (58,083), and Australia (19,617 patients). Lung cancer is the most common cancer, and had 8,15,563 new cases in China and 2,27,875 new cases in the USA. Also, for thyroid cancer, China had 2,21,093 new cases, followed by the USA with 52,912 new cases in 2020. Pancreatic cancer was also most prevalent in China (54,611), the USA (26,798), and Japan (22,496). With the growing burden of cancer cases, the EGFR Inhibitors market is also expected to grow.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
Afatinib, Almonertinib, Brigatinib, Dacomitinib, Erlotinib, Gefitinib, Lapatinib, Neratinib, and Pyrotinib are some of the approved EGFR inhibitors.
Amgen, AstraZeneca, Boehringer Ingelheim, Jiangsu Hengrui Pharma, Sanofi, Daiichi Sankyo Company, and Eli Lilly & Company are some of the major players in the EGFR inhibitors market.
Major indications for EGFR inhibitors are non-small cell lung cancer, breast cancer, thyroid cancer, pancreatic cancer, and solid tumors.
There are more than 100 drug molecules in the clinical development phases for EGFR inhibitors.
- Amgen
- AstraZeneca
- Boehringer Ingelheim
- Jiangsu Hengrui Pharma
- Sanofi
- Daiichi Sankyo Company
- Betta Pharmaceuticals
- Pfizer
- Takeda
- Genmab
- J&J
- Eli Lilly & Company